Autonomix medical, inc. granted approval to expand proof-of-concept human clinical study, doubling potential addressable market beyond pancreatic cancer pain

Follow-on study (“poc 2”) builds on initial success in pancreatic cancer pain  ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology expansion supports autonomix's strategy to build long-term value through multi-indication growth patient enrollment expected to begin in june 2025 the woodlands, tx, june 05, 2025 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has received ethics committee authorization from the ministry of health of the republic of uzbekistan to open the clinical trial site for the follow-on phase to its proof-of-concept human clinical trial (“poc 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate cancer pain. the company is on track to commence enrollment in june 2025.
AMIX Ratings Summary
AMIX Quant Ranking